Digene Acquisition Clears Antitrust Waitng Period
From Associated Press:
Qiagen's acquisition of Gaithersburg-based Digene, a maker of gene-based medical tests, has cleared an antitrust waiting period, the companies said today in a statement.
Netherlands-based Qiagen, a diagnostic products maker, agreed to purchase Digene last month in a cash-and-stock deal worth approximately $1.6 billion. The expiration of the antitrust waiting period completes a condition required to close the acquisition.
The transaction is expected to close in August or September, subject to Qiagen shareholder approval and the tender of a majority of Digene's stock before July 20, unless the tender period is extended.
Please email us to report offensive comments.
The comments to this entry are closed.